ANGLE Reports FY2024 Results with Narrowed Loss and Continued Focus on Pharma Collaborations

ANGLE plc (LSE:AGL),a UK-based liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has released its audited preliminary financial results for the year ended 31 December 2024. The company reported a reduction in operating loss alongside a revenue increase, following operational restructuring and …

Team Kalkine | 28 May 2025

Poolbeg Pharma Gains FDA Orphan Drug Status for Groundbreaking CRS Prevention Treatment

Highlights

Team Kalkine | 27 May 2025

Poolbeg Pharma Raises £4.87M to Advance Clinical Trials, Extends Cash Runway to 2027

Highlights

Team Kalkine | 23 May 2025

IXICO Releases First-Half Results, On Track to Exceed 2025 Expectations

Highlights

Team Kalkine | 20 May 2025

Poolbeg Pharma Launches £4.1 Million Fundraise to Advance Cancer and Obesity Treatments

Highlights

Team Kalkine | 20 May 2025

Arecor (AIM: AREC) and Skye Bioscience Collaborate on Enhanced Formulation of Obesity Drug Candidate

Arecor Therapeutics plc (AIM: AREC)has announced a new collaboration with US-based Skye Bioscience (Nasdaq: SKYE) to develop a higher concentration formulation of nimacimab, a monoclonal antibody currently under investigation for the treatment of obesity and related metabolic conditions.

Team Kalkine | 19 May 2025

Genflow Biosciences Advances SIRT6 Gene Therapy Patent in Japan

Highlights

Team Kalkine | 15 May 2025

GSK Acquires Promising Liver Disease Drug Efimosfermin in $2 Billion Deal to Tackle Global Hepatology Crisis

In a strategic move to bolster its liver disease portfolio, GSK plc (LSE:GSK) has announced the acquisition of efimosfermin alfa, a promising investigational treatment for steatotic liver disease (SLD), from Boston Pharmaceuticals. The deal, valued at $2 billion, includes an upfront payment of $1.2 …

Team Kalkine | 14 May 2025

GSK Delivers Positive Start to 2025 with Surge in Specialty Medicines and Robust Pipeline Momentum

GSK reported Q1 2025 sales of £7.5 billion, driven by a 17% rise in Specialty Medicines and signifucant growth in HIV and oncology treatments.

Team Kalkine | 30 April 2025

Smith+Nephew Delivers Q1 Revenue Growth, Maintains 2025 Outlook Amid Global Headwinds

Highlights:

Team Kalkine | 30 April 2025

Healthcare

ANGLE Reports FY2024 Results with Narrowed Loss and Continued Focus on Pharma Collaborations

Poolbeg Pharma Gains FDA Orphan Drug Status for Groundbreaking CRS Prevention Treatment

Poolbeg Pharma Raises £4.87M to Advance Clinical Trials, Extends Cash Runway to 2027

IXICO Releases First-Half Results, On Track to Exceed 2025 Expectations

Poolbeg Pharma Launches £4.1 Million Fundraise to Advance Cancer and Obesity Treatments

Arecor (AIM: AREC) and Skye Bioscience Collaborate on Enhanced Formulation of Obesity Drug Candidate

Genflow Biosciences Advances SIRT6 Gene Therapy Patent in Japan

GSK Acquires Promising Liver Disease Drug Efimosfermin in $2 Billion Deal to Tackle Global Hepatology Crisis

GSK Delivers Positive Start to 2025 with Surge in Specialty Medicines and Robust Pipeline Momentum

Smith+Nephew Delivers Q1 Revenue Growth, Maintains 2025 Outlook Amid Global Headwinds

Latest News

Schroder British Opportunities Trust - UK Growth Trust Moves Again With Share Transaction

The Bankers Investment Trust - Global Dividend Trust Returns to Focus After Share Transaction

Corero Network Security - The Cybersecurity Stock Built for the DDoS Threat Era

Polar Capital Holdings - Asset Manager Draws Fresh Interest After Own-Share Transaction

Loomis - Cash-Handling Group Expands in Argentina With Acquisition Move

BlackRock Energy and Resources Income Trust - Resources Income Trust Back in Focus After Buyback Activity